These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25463593)

  • 1. Type I interferonopathies: mendelian type I interferon up-regulation.
    Crow YJ
    Curr Opin Immunol; 2015 Feb; 32():7-12. PubMed ID: 25463593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferonopathies: a novel set of inborn errors of immunity.
    Crow YJ
    Ann N Y Acad Sci; 2011 Nov; 1238():91-8. PubMed ID: 22129056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Type I interferonopathies].
    Munoz J; Marque M; Dandurand M; Meunier L; Crow YJ; Bessis D
    Ann Dermatol Venereol; 2015 Nov; 142(11):653-63. PubMed ID: 26363997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic interferonopathies: An overview.
    Eleftheriou D; Brogan PA
    Best Pract Res Clin Rheumatol; 2017 Aug; 31(4):441-459. PubMed ID: 29773266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I interferonopathies in pediatric rheumatology.
    Volpi S; Picco P; Caorsi R; Candotti F; Gattorno M
    Pediatr Rheumatol Online J; 2016 Jun; 14(1):35. PubMed ID: 27260006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.
    Yu ZX; Song HM
    World J Pediatr; 2020 Feb; 16(1):44-51. PubMed ID: 31377974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies.
    Pescarmona R; Belot A; Villard M; Besson L; Lopez J; Mosnier I; Mathieu AL; Lombard C; Garnier L; Frachette C; Walzer T; Viel S
    Cytokine; 2019 Jan; 113():446-452. PubMed ID: 30413290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The eukaryotic elongation factor eEF1A1 interacts with SAMHD1.
    Morrissey C; Schwefel D; Ennis-Adeniran V; Taylor IA; Crow YJ; Webb M
    Biochem J; 2015 Feb; 466(1):69-76. PubMed ID: 25423367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aicardi-Goutières syndrome and the type I interferonopathies.
    Crow YJ; Manel N
    Nat Rev Immunol; 2015 Jul; 15(7):429-40. PubMed ID: 26052098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Type I Interferonopathies.
    Lee-Kirsch MA
    Annu Rev Med; 2017 Jan; 68():297-315. PubMed ID: 27813875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferonopathies: From concept to clinical practice.
    Mendonça LO; Frémond ML
    Best Pract Res Clin Rheumatol; 2024 Sep; 38(3):101975. PubMed ID: 39122631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA Editing in Interferonopathies.
    Frassinelli L; Galardi S; Ciafrè SA; Michienzi A
    Methods Mol Biol; 2021; 2181():269-286. PubMed ID: 32729086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of samhd1 morphant zebrafish recapitulates features of the human type I interferonopathy Aicardi-Goutières syndrome.
    Kasher PR; Jenkinson EM; Briolat V; Gent D; Morrissey C; Zeef LA; Rice GI; Levraud JP; Crow YJ
    J Immunol; 2015 Mar; 194(6):2819-25. PubMed ID: 25672750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I Interferonopathies: A Clinical Review.
    Wang CS
    Rheum Dis Clin North Am; 2023 Nov; 49(4):741-756. PubMed ID: 37821193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Type I interferonopathies. Literature review].
    Picard C; Belot A
    Rev Med Interne; 2018 Apr; 39(4):271-278. PubMed ID: 27659742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-Stimulated Gene Expression as a Preferred Biomarker for Disease Activity in Aicardi-Goutières Syndrome.
    Wang BX; Grover SA; Kannu P; Yoon G; Laxer RM; Yeh EA; Fish EN
    J Interferon Cytokine Res; 2017 Apr; 37(4):147-152. PubMed ID: 28387595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy.
    Troedson C; Wong M; Dalby-Payne J; Wilson M; Dexter M; Rice GI; Crow YJ; Dale RC
    Lupus; 2013 May; 22(6):639-43. PubMed ID: 23651859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDA5 and autoimmune disease.
    Miner JJ; Diamond MS
    Nat Genet; 2014 May; 46(5):418-9. PubMed ID: 24769716
    [No Abstract]   [Full Text] [Related]  

  • 19. IFN-signaling gene expression as a diagnostic biomarker for monogenic interferonopathies.
    Adang LA; D'Aiello R; Takanohashi A; Woidill S; Gavazzi F; Behrens EM; Sullivan KE; Goldbach-Mansky R; de Jesus AA; ; Vanderver A; Shults J
    JCI Insight; 2024 Jun; 9(14):. PubMed ID: 38885315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation.
    La Maestra S; Frosina G; Micale RT; D'Oria C; Garibaldi S; Daga A; Pulliero A; Izzotti A
    Drug Deliv Transl Res; 2018 Oct; 8(5):1345-1354. PubMed ID: 29869293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.